T 1684/16 du 03.03.2020
- Identifiant européen de la jurisprudence
- ECLI:EP:BA:2020:T168416.20200303
- Date de la décision
- 3 mars 2020
- Numéro de l'affaire
- T 1684/16
- Requête en révision de
- -
- Numéro de la demande
- 06774184.3
- Classe de la CIB
- A61K 31/4709C07D 215/54
- Langue de la procédure
- Anglais
- Distribution
- Non distribuées (D)
- Téléchargement
- Décision en anglais
- Versions JO
- Aucun lien JO trouvé
- Autres décisions pour cet affaire
- -
- Résumés pour cette décision
- -
- Titre de la demande
- CRYSTALLINE FORMS OF 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-METHOXY-7-[3-(4-METHYL-1-PIPERAZINYL)PROPOXY]-3-QUINOLINECARB-ONITRILE AND METHODS OF PREPARING THE SAME
- Nom du demandeur
- Wyeth LLC
- Nom de l'opposant
- Fresenius Kabi Deutschland GmbH
Generics [UK] Ltd (trading as Mylan) - Chambre
- 3.3.02
- Sommaire
- -
- Dispositions juridiques pertinentes
- European Patent Convention Art 100(c) (2007)European Patent Convention Art 56 (2007)Rules of procedure of the Boards of Appeal Art 13(1) (2007)Rules of procedure of the Boards of Appeal Art 13(3) (2007)
- Mots-clés
- Grounds for opposition - amendments
New allegation of facts
Inventive step - Exergue
- The fact that the skilled person is taught in the prior art to investigate polymorphs in order to isolate the crystalline form having the most desirable properties is in itself not necessarily sufficient to consider a specific polymorphic form having a certain desired property obvious (see point 4.3.4 of the Reasons).
- Affaires citées
- T 0777/08
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent with the following claims and a description to be adapted thereto:
claims 1 to 21 of the first auxiliary request, filed with the reply to the statement of grounds of appeal.